Overview: Luteinizing Hormone (LH) Marker Rapid TestIntroduction: The Luteinizing Hormone (LH) Marker Rapid Test is a diagnostic tool designed to detect LH levels in serum or urine samples, facilitating the screening of infertility or hormonal imbalances. Associated with conditions like polycystic ovary syndrome or hypogonadism, this endocrine disorder presents with irregular periods, infertility, and severe complications like osteoporosis if untreated, particularly in individuals during reproductive transitions. Per the 2023 Endocrine Society guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in endocrinology or gynecology settings. This rapid diagnostic falls under endocrinology and targets individuals with reproductive or hormonal symptoms, addressing the challenge of early detection to guide hormone therapy or fertility treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing complications. Its multi-sample capability enhances its utility.Other Names: LH Rapid Test.FDA Status: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Beckman Coulter, this test advanced hormone detection, providing a rapid alternative to traditional assays.Purpose: The test screens for LH to guide infertility or hormonal imbalance diagnosis, assess reproductive status, and inform treatment and prevention strategies.Test Parameters: Presence of LH, detected with reasonable specificity to indicate hormonal function, typically detectable in serum or urine at abnormal levels during active disease.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report irregular periods, infertility, or menopausal symptoms.Specimen: Serum 2-5 mL, Urine 5-20 mL, collected using sterile SST or containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve marker integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade markers, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on irregular periods, infertility, hot flashes, or prior hormonal issues, as well as any family history of endocrine disease or recent stress.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated conditions including osteoporosis, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent hormone therapy can affect results. Correlation with FSH or ultrasound is recommended to confirm findings.Clinical Significance: A positive result indicates possible infertility or hormonal imbalance, necessitating further investigation like FSH levels or endocrinology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during stable periods.Specialist Consultation: Endocrinologists or gynecologists should be consulted for case management, treatment planning, and coordination with endocrine disease programs.Additional Supporting Tests: FSH, estradiol, or ultrasound for confirmation.Test Limitations: The test may produce false positives in pregnancy or false negatives in early disease, requiring a comprehensive diagnostic approach that includes clinical correlation.References: ES Guidelines 2023, Journal of Endocrinology 2024, Biochemistry 2025.